Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifungal susceptibility testing.

Annette W Fothergill1, Michael G Rinaldi, Deanna A Sutton

  • 1Fungus Testing Laboratory, Department of Pathology, University of Texas Health Science Center at San Antonio, TX 78229, USA. fothergill@uthscsa.edu

Infectious Disease Clinics of North America
|September 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shielding the Next Generation: Symbiotic Bacteria from a Reproductive Organ Protect Bobtail Squid Eggs from Fungal Fouling.

mBio·2019
Same author

Novel Paranannizziopsis species in a Wagler's viper (Tropidolaemus wagleri), tentacled snakes (Erpeton tentaculatum), and a rhinoceros snake (Rhynchophis boulengeri) in a zoological collection.

Medical mycology·2018
Same author

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

mBio·2018
Same author

Species of Aspergillus section Aspergillus from clinical samples in the United States.

Medical mycology·2018
Same author

New Species Spiromastigoides albida from a Lung Biopsy.

Mycopathologia·2017
Same author

Four new species of Talaromyces from clinical sources.

Mycoses·2017
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Antifungal susceptibility testing (AST) aids clinical decisions for difficult fungal infections. While trends are known, correlation data is limited, yet AST remains valuable for patient care.

Area of Science:

  • Mycology
  • Clinical Microbiology
  • Infectious Diseases

Background:

  • Antifungal susceptibility testing (AST) has been a routine clinical tool for over 15 years.
  • It assists clinicians in managing challenging fungal infections.
  • Despite its use, significant confusion persists regarding the interpretation of AST results.

Purpose of the Study:

  • To evaluate the current utility and challenges of antifungal susceptibility testing in clinical practice.
  • To highlight the existing knowledge gaps, particularly in correlation data.

Main Methods:

  • Review of existing data on antifungal susceptibility testing trends.
  • Analysis of the correlation between in vitro susceptibility and clinical outcomes.

Related Experiment Videos

Main Results:

  • Sufficient data exist to establish susceptibility trends for various fungi against specific antifungal agents.
  • However, minimal correlation data is available to link these in vitro results to clinical treatment efficacy.
  • Clinicians frequently utilize AST despite these data limitations.

Conclusions:

  • Antifungal susceptibility testing provides valuable information for patient care, even with limited correlation data.
  • Further research is needed to strengthen the correlation between in vitro susceptibility and clinical outcomes.
  • Continued education on interpreting AST results is crucial for clinicians.